Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Discoveresearch Inc

Neither a doctor nor a teaching hospital

Research payments

$1,259,578

271 payments

Through program year 2024, Discoveresearch Inc is reported as receiving $1,259,578 in research payments, across 271 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $50,143 2
2023 Research $159,826 21
2022 Research $248,083 48
2021 Research $205,697 107
2020 Research $227,162 60
2019 Research $368,666 33

Breakdown

Who paid Research payments · program years 2019–2024
  1. Allergan Inc. $461,252 81 payments
  2. Eli Lilly and Company $260,462 9 payments
  3. Endo Pharmaceuticals Inc. $223,834 84 payments
  4. AbbVie, Inc. $165,520 40 payments
  5. Boehringer Ingelheim Pharmaceuticals, Inc. $63,879 5 payments
  6. GlaxoSmithKline, LLC. $60,845 46 payments
  7. Galderma Research & Development, LLC $12,918 3 payments
  8. Novartis Pharmaceuticals Corporation $9,867 1 payment
  9. Biohaven Pharmaceuticals, Inc. $1,000 2 payments
Studies the money was for Research payments · program years 2019–2024
  1. A Phase 3B, Open-Label, Long-Term Study to Evaluate the Safety and Temporal Pattern of Response of En3835 in the Treatment of Edematous Fibrosclerotic Panniculopathy $223,834 84 payments
  2. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $217,309 18 payments
  3. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (Summit $162,141 5 payments
  4. Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine $138,461 21 payments
  5. A Randomized Double-Blind Placebo-Controlled Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (Summit $96,994 2 payments
  6. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Treatment of Migraine When Adminstered During the Premonitory Phase $95,942 15 payments
  7. Exercise capacity study in HFpEF $38,234 3 payments
  8. Menb Rec 2Nd Gen-023 (V72_57) $35,667 22 payments
  9. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Treatment of Migraine When Adminstered During the Premonitory Phase $31,015 8 payments
  10. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine $30,200 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record